Risdiplam approved for use in EU for the treatment of spinal muscular atrophy

Risdiplam, a survival motor neuron 2 (SMN2)-directed RNA splicing modifier, was approved in patients 2 months and older on the basis of efficacy results from the FIREFISH and SUNFISH studies in children and young adults with SMA.

Source:

Biospace Inc.